18F-NaF PET Imaging for Bone Scintigraphy

PHASE3CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2019

Conditions
Bone Metastases From Breast or Prostate Cancer
Interventions
PROCEDURE

NaF PET/CT Imaging

Diagnostic imaging test that is considered investigational

PROCEDURE

99mTc-medronate whole body bone scan with SPECT

99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.

DRUG

18F-Sodium Fluoride (NaF)

A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours

Trial Locations (10)

T6G 1Z2

Edmonton Cross Cancer Institute, Edmonton

V5Z 4E6

BC Cancer Agency, Vancouver

B3H 2Y9

QEII Health Sciences Centre, Halifax

L8N 3Z5

Hamilton Health Sciences Corp., Hamilton

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

N6A 5A5

London Health Sciences Centre, London

K1H 8L6

The Ottawa Hospital, Ottawa

M5G 2M9

University Health Network, Toronto

J1H 5N4

Centre hospitalier universitaire de Sherbrooke, Fleurimont

H2L 4M1

Centre hospitalier universitaire de Montréal, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

British Columbia Cancer Agency

OTHER

NCT01930812 - 18F-NaF PET Imaging for Bone Scintigraphy | Biotech Hunter | Biotech Hunter